Robeco Institutional Asset Management B.V. Sells 484,651 Shares of Hologic, Inc. (NASDAQ:HOLX)

Robeco Institutional Asset Management B.V. trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 69.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 211,786 shares of the medical equipment provider’s stock after selling 484,651 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.09% of Hologic worth $15,132,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. McGlone Suttner Wealth Management Inc. bought a new stake in shares of Hologic during the 4th quarter valued at $27,000. Venturi Wealth Management LLC bought a new position in Hologic in the 3rd quarter worth about $29,000. NBC Securities Inc. bought a new position in Hologic in the 3rd quarter worth about $33,000. Deseret Mutual Benefit Administrators increased its stake in Hologic by 42.2% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 155 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its stake in Hologic by 69.4% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 227 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Hologic Trading Up 0.1 %

NASDAQ HOLX traded up $0.07 on Friday, hitting $75.02. The company’s stock had a trading volume of 1,451,370 shares, compared to its average volume of 1,389,154. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $82.45. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The company’s 50-day simple moving average is $76.25 and its 200 day simple moving average is $73.66. The firm has a market cap of $17.51 billion, a P/E ratio of 38.28, a PEG ratio of 2.50 and a beta of 1.01.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the business posted $1.06 EPS. The business’s revenue was down .8% on a year-over-year basis. Research analysts predict that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Argus upped their target price on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. UBS Group upped their price objective on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Friday, May 3rd. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $85.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.